Trieste, 31 July 2025 – Ulisse Biomed S.p.A. (“UBM” or the “Company” or the “Group”), an Italian healthcare biotech company operating in the fields of diagnostics, theranostics and therapeutics, announces that today has signed an investment agreement (the “Agreement”) with the U.S. based entities Global Corporate Finance (the “Investor”) and Sterling Atlantic, LLC (“SAP”).

Trieste, 31 luglio 2025 – Ulisse Biomed S.p.A.

IL CONSIGLIO D’AMMINISTRAZIONE PRENDE VISIONE DEI DATI CONSOLIDATI AL 30 GIUGNO 2025 RICAVI VENDITE CONSOLIDATI PARI AD EURO C. 14 MILIONI (15,3 MILIONI AL 30.06.24) RICAVI SEMI, END-MARKET INDUSTRIAL & AI, IN CRESCITA DEL 28% RISPETTO AL 30.06.24